NK - NantKwest (NK) soars 61% on ImmunityBio achieving primary endpoint in bladder cancer study with 72% complete response

NantKwest surges 61% premarket after its partner ImmunityBio announces positive data from the first cohort of a Phase 2/3 trial (QUILT 3.032) of IL-15 fusion protein, Anktiva, for non-muscle invasive bladder cancer in high risk carcinoma in situ ((CIS)) disease.The data showed 51 out of 71 evaluable patients (72%) had a complete response (at any time) to intravesical BCG plus N-803 (Anktiva), with 59% probability of these patients maintaining a complete response for at least 12 months, with a median duration of complete response of 19.2 months to date. The primary endpoint for Cohort A of this Phase 2/3 study is incidence of complete response of CIS at any time. The FDA had granted Fast Track Designation to the pivotal trial based on Phase I data.“We expect to file a Biologics License Application following a meeting with the FDA in 2021,” said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio. The cytokine interleukin-15 (IL-15) plays a

For further details see:

NantKwest (NK) soars 61% on ImmunityBio achieving primary endpoint in bladder cancer study with 72% complete response